Composite adjuvant for animal vaccine, preparation method and vaccine

An adjuvant and vaccine technology, applied in the field of preparation of animal vaccines, can solve the problems affecting the absorption of adjuvants in the injection experience of finished products, and achieve the effects of stimulating humoral immune response, high antigen load, and avoiding viscosity increase

Pending Publication Date: 2021-12-17
浙江洪晟生物科技股份有限公司 +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the process of emulsification production, in order to stabilize the dosage form, the upper limit of the ratio of the antigen must be strictly controlled; at the same time, the antigen is used as the water phase, and as the addition of the water phase increases, the viscosity of the emulsified product will also increase, which affects the injection experience and adjuvant of the finished product. Drug absorption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite adjuvant for animal vaccine, preparation method and vaccine
  • Composite adjuvant for animal vaccine, preparation method and vaccine
  • Composite adjuvant for animal vaccine, preparation method and vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] (1) Mix squalene, SPAN85 and TWEEN 80 in a weight ratio of 134:23:43, stir at a speed of 150rpm for 30min, and stand still to obtain a transparent solution;

[0043] (2) Prepare the water phase: the inactivated PCV2 cell culture that is qualified in the sterility test is the water phase;

[0044] (3) Mix the solution obtained in step (1) again, then add it to the water phase at a volume ratio of water phase: oil phase = 6:1, emulsify under stirring at 150 rpm, and stand to obtain an oil-in-water vaccine. Take a small amount of the finished product and drop it on the surface of cold water, and it spreads in the form of cloud mist, which is oil-in-water type; take 10ml of the finished product and centrifuge at 3000r / min for 15 minutes, no water phase precipitates at the bottom of the tube; store it at 4°C and 37°C for 28 days, no Separation occurs and the resulting vaccine is a stable emulsion.

[0045](4) The finished product is measured with a rotary viscometer to have...

Embodiment 2

[0048] (1) Mix squalene, SPAN85, TWEEN 80 and saponin in a weight ratio of 12:2:5:1, stir at 150rpm for 40min, and stand still to obtain a transparent solution;

[0049] (2) Prepare the water phase: the inactivated PCV2 cell culture that is qualified in the sterility test is the water phase;

[0050] (3) Re-mix the solution obtained in step (1), then add it to the water phase at a volume ratio of water phase: oil phase = 8:1, emulsify under stirring at 150 rpm, and stand to obtain an oil-in-water vaccine. Take a small amount of finished product and drop it on the surface of cold water, and it spreads in the form of cloud, which is oil-in-water type; take 10ml of finished product and centrifuge at 3000r / min for 15 minutes, no water phase precipitates at the bottom of the tube; store at 4°C and 37°C for 28 days, no Stratification occurs and the resulting vaccine is a stable emulsion.

[0051] (4) The finished product is measured with a rotary viscometer to have a viscosity of 5...

Embodiment 3

[0061] Embodiment 3: mouse immune test

[0062] 1. Test materials

[0063] Table 1: Vaccine Information

[0064]

[0065] Table 2: Kit information

[0066]

[0067] 3. Experimental mice: purchased from Hangzhou Normal University, about 30 days old. Among them, there were 11 male mice and 14 female mice. Every 5 male mice were divided into 1 group, a total of 2 groups, and the remaining 1 was used as the control group; every 5 female mice were divided into 1 group, a total of 2 groups, and the remaining 4 were used as the control group.

[0068] 2. Immunization procedure: one group (5 rats / group) of male mice and one group of female rats were selected to be immunized with 0.2ml / mouse of the cyclinox vaccine; the remaining two groups (5 rats / group) were immunized with HS1010 emulsified vaccine, 0.2ml / mouse; The control group was injected with normal saline, 0.2ml / rat.

[0069] Twenty-eight days after the first immunization, 2 animals were selected from the Verdil vacc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Login to view more

Abstract

The invention relates to a composite adjuvant for an animal vaccine, a preparation method and the vaccine. In one embodiment, the composite adjuvant is made by emulsifying a composition of squalene, SPAN85, and TWEEN 80. In another embodiment, the composite adjuvant is made by emulsifying a composition of squalene, SPAN85, TWEEN 80, and a saponin. By utilizing the method provided by the invention, the animal vaccine adjuvant can cooperate with the antigen for use at a relatively high ratio and has good biocompatibility and stability.

Description

technical field [0001] The invention relates to the field of preparing animal vaccines, in particular to a compound adjuvant for animal vaccines, a preparation method and a vaccine. Background technique [0002] Vaccine adjuvants are substances that can non-specifically change or enhance the body's specific immune response to antigens and play an auxiliary role. The adjuvant can induce the body to produce a long-term and efficient specific immune response, improve the body's protective ability, and at the same time reduce the amount of immune substances and reduce the production cost of the vaccine. In recent years, in order to meet the needs of new vaccines, adjuvants have developed from traditional and single forms to new and diversified forms, especially the research on adjuvants for mucosal vaccines, DNA vaccines and tumor vaccines has become a hot spot. [0003] At present, in animal vaccines, mineral oil adjuvants are commonly used as adjuvants, and the volume ratio o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61K9/107
CPCA61K39/39A61K9/107A61K2039/55566A61K2039/55511A61K2039/55577
Inventor 舒建洪何玉龙冯华朋李遥张丰昌陈晓威
Owner 浙江洪晟生物科技股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap